Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
Q4 2023 vs. Q3 2023
How the institutions holding Estrella Immunopharma, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 0 | 7 | +7 |
| Shares | 0 | 128.6K | +128.6K |
| Value | $0 | $143.2K | +$143.2K |
New holders (7)
Institutions that held Estrella Immunopharma, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 56,215 | $63.0K | 0.00% |
| Atw Spac Management LLC | 40,000 | $44.4K | 0.06% |
| Hunting Hill Global Capital, LLC | 21,358 | $23.7K | 0.02% |
| Maso Capital Partners Ltd | 10,000 | $11.0K | 0.01% |
| Tower Research Capital LLC (TRC) | 632 | $702 | 0.00% |
| UBS Group AG | 303 | $336 | 0.00% |
| Wells Fargo & Company | 73 | $81 | 0.00% |
Sold out (0)
Institutions that held Estrella Immunopharma, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
None.